Zymeworks Inc.’s Post

🎗️W𝗼𝗿𝗹𝗱 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆: 𝗦𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗶𝗴𝗵𝘁 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 ⁣ At Certest Pharma, we stand for the World Breast Cancer Day and those who are affected and committed to supporting the fight from a scientific perspective. In recent years, groundbreaking 𝗥𝗡𝗔-𝗯𝗮𝘀𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 have opened new possibilities in the treatment of #breastcancer, offering hope and innovative solutions for patients. We are proud to be part of a field that is pushing the boundaries of science to develop more targeted and effective treatments. 💊Together, through innovation and research, we can make strides in the fight against breast cancer. #CertestPharma #WorldBreastCancerDay #BreastCancerAwareness  

Shine a light on hope this May! Bladder, brain, and skin cancers are seeing brighter outlooks thanks to evolving treatments, including #radiopharmaceutical therapies! Let's raise awareness and celebrate progress in the fight against cancer. 💡 Did you know that our website can keep you updated about the latest advancements in #radiotheranostics for cancer care? This is part of our mission to spread the word about this life-changing technology. Check it out: https://buff.ly/3WGVYAs #cancerawareness #radiotheranostic #nuclearmedicine

In this exclusive interview, we have a special guest, Dr. Reggie Ewesuedo, Vice President of Clinical Development at Lantern Pharma Inc. (Nasdaq: LTRN), to discuss 'Breakthrough in #LungCancer Treatment for Never Smokers' including the novel #AI-assisted drug candidate #LP300. We'll dive into the promising results of the #HARMONIC Phase 2 trial, focusing on LP-300 and its significant implications for treating #lung #cancer. Additionally, we’ll explore the transformative role of #artificialintelligence in #drugdiscovery, particularly how it's reshaping #clinicaltrials and treatment strategies. https://lnkd.in/dVbpWEmm

Our world is changing: for the GOOD. Todays conference discussion: Unscreened cancers account for ~70% of US cancer deaths; however, early diagnosis is transformative, with up to an 89% survival rate, depending on the disease and stage. Multi-cancer early detection (MCED) tests are a new simple blood-based solution to screen for multiple cancers. We will share our approach to MCED, which fuels our mission: to detect cancer early—when it can be cured. #MCED #earlycancerdeyection

From new approvals and shortages to precision medication, change and innovation seem to be the only constants in oncology. See more on the trends, breakthroughs and challenges shaping cancer care. ⬇️ Download the report: http://spr.ly/6049Uwi33

From new approvals and shortages to precision medication, change and innovation seem to be the only constants in oncology. See more on the trends, breakthroughs and challenges shaping cancer care. ⬇️ Download the report: http://spr.ly/6047evuBP

From new approvals and shortages to precision medication, change and innovation seem to be the only constants in oncology. See more on the trends, breakthroughs and challenges shaping cancer care. ⬇️ Download the report: http://spr.ly/6047ei13T

Oncology navigators often use many tools to support their unique workflows and follow up management for cancer patients. Click the link below to see how some of those tools compare and how OncoNav is the best platform for navigation needs. → https://lnkd.in/e9Fa8nAX

Watch the on-demand presentation, Leading the Way: Approaches in Biomarker Testing, a Standardized Approach, for details on building relationships and providing educational support to your colleagues. Gain insight on building a consensus for standardized biomarker testing for homologous recombination deficiency, also referred to as HRD, in patients with advanced ovarian cancer from Dr S. Michelle Shiller, DO, AP/CP, MGP. https://bit.ly/3WZH9aW

Excellent panel here.